Neurofibromatosis Type 1(NF1; Von Recklinghausen Disease)
by
Cynthia M. Johnson, MA DefinitionNeurofibromatosis is a genetic problem that causes tumors in the nervous system. Tumors develop in the nerves or the tissue that surrounds the nerves, called the myelin sheath. Neurofibromatosis is divided into 3 types, neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. The type is determined by the specific genes that are affected. This articles discusses NF1, the most common neurofibromatosis. It affects the nerves outside the brain and spinal cord, called peripheral nerves.
CausesNF is caused by a change in a specific gene. The gene normally makes proteins that help control growth in the nerves. Since the gene is defective, these proteins are not able to control growth, and tumors develop. In many cases, the abnormal gene is inherited from a parent. A person with the inherited form of NF has a 50% chance of passing the abnormal gene to each child. Any parents, children, and siblings of an affected individual should be considered at risk for NF. However, the gene change can occur in a person with no family history of NF. Risk FactorsThe main risk factor for NF is having a family member with the disease. SymptomsMost symptoms begin between birth and age 10. NF1 may cause:
Other medical conditions that are associated with NF1 include:
DiagnosisYou will be asked about your medical and family medical history. A physical exam will be done. It may take a few years before NF1 is diagnosed. NF1 may be suspected if there is a history of:
Images may be taken of your nerves and brain. This can be done with an MRI scan. Samples of tumors may also be removed and sent for a biopsy. Genetic testing may be recommended for families with a history of neurofibromatosis. Prenatal diagnosis may also be possible with amniocentesis or chorionic villus sampling. You may be referred to specialists to look for signs of tumors of the nervous system. TreatmentThere are no current treatments to stop these tumors from growing. Treatment may not be needed since these tumors are rarely cancerous, grow slowly, and may not cause problems. Regular exams are recommended to check for new tumors or symptoms. Treatment may be needed to control symptoms. Surgery may be done to remove painful or disfiguring tumors. Medications and therapies may also be needed to manage other symptoms such as seizures and learning disabilities. Rarely, some tumors can become cancerous. These tumors may need to be treated with surgery, chemotherapy, or radiation therapy. PreventionThere are no current guidelines to prevent neurofibromatosis. RESOURCES:Children's Tumor Foundation http://www.ctf.org Neurofibromatosis Network http://www.nfnetwork.org CANADIAN RESOURCES:Health Canada https://www.canada.ca Tumour Foundation of BC http://www.tumourfoundation.ca/ References:Neurofibromatosis. Children's Tumor Foundation website. Available at: ...(Click grey area to select URL) Accessed January 28, 2021. Neurofibromatosis type 1. EBSCO DynaMed website. Available at: ...(Click grey area to select URL) Accessed January 28, 2021. Neurofibromatosis (N1, N2). Your Genes Your Health website. Available at: ...(Click grey area to select URL) Accessed January 28, 2021. NINDS neurofibromatosis information page. National Institute of Neurological Disorders and Stroke website. Available at:
https://www.ninds.nih.gov/Disorders/All-Disorders/Neurofibromatosis-Information-Page. Accessed January 28, 2021. Last reviewed March 2020 by
EBSCO Medical Review Board
Chelsea Skucek, MSN, BS, RNC-NIC Last Updated: 01/28/2021 |
|
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation. This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition. To send comments or feedback to our Editorial Team regarding the content please email us at healthlibrarysupport@ebsco.com. Our Health Library Support team will respond to your email request within 2 business days. |